SCRS and NAVREF Announce Partnership
Ellicott City, MD – The Society for Clinical Research Sites (SCRS) and the National Association of Veterans’ Research and Education Foundations (NAVREF) are pleased to announce an alliance between the two organizations. This relationship will provide SCRS membership, mentoring and training, and other elements to NAVREF members. NAVREF is the nonprofit research and education association with 80 member sites affiliated with Department of Veterans Affairs medical centers. “Research sites associated with Department of Veterans Affairs medical centers have not always had an easy time making a good fit with industry-sponsored clinical trials,” said Christine Pierre, President of SCRS. “We are dedicated to assisting NAVREF establish VA associated research sites as first in class sites enabling them to offer clinical research opportunities to our veterans and their families.” “We are thrilled to be joining forces with SCRS,” said Rick Starrs, CEO of NAVREF. “Our nonprofit foundations and the VA have been actively working to deliver more clinical research studies to veterans. This partnership with SCRS will bring NAVREF closer to achieving our vision of a nation in which veterans receive the finest care based on innovative research and education.” About SCRS SCRS is a global trade organization founded in 2012 which represents over 3,000 research sites in 49 countries. SCRS’ mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites and the companies that sponsor or support the work conducted at clinical research sites will benefit from membership and partnership. Visit
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025